Avalo Therapeutics Appoints Stephen Smolinski as Chief Commercial Officer – QNT Press Release

WAYNE, Pa. and ROCKVILLE, Md., Jan. 10, 2022 (GLOBE NEWSWIRE) — Avalo Therapeutics, Inc. (NASDAQ:AVTX) (“Avalo” or the “Company”), a leading clinical-stage precision medicine company, discovering, developing and commercializing targeted therapies for patients with significant unmet clinical needs in immunology, immuno-oncology and rare genetic diseases Pharma, today announced the appointment of Stephen Smolinski as Chief Commercial Officer, effective January 3, 2022.

“We are delighted to welcome Stephen to our leadership team,” said Mike Cola, CEO of Avalo Therapeutics. “Stephen has over 25 years of experience in defining and implementing commercial and business development strategies. He is well suited to spearhead the development of Avalo’s commercial capabilities and help guide business development activities to identify opportunities for partner assets as appropriate, and support activities for Avalo Provides strategically aligned new opportunities to complement the company’s portfolio. On behalf of the Avalo team, I thank Jamie Harrell, who previously served as our Chief Commercial Officer, for his contributions to Avalo and wish him all the best in his future endeavors.”

As Chief Commercial Officer, Mr. Smolinski will lead Avalo’s commercial team, including launch readiness programs, and play a key role in the development and execution of the company’s “go-to-market” strategy. Prior to joining Avalo, Mr. Smolinski was Global Head of Immunology Therapeutics for Orphan Biovitrum AB (Sobi™) in Sweden. Prior to that, Mr. Smolinski served as Chief Commercial Officer of Selecta Biosciences, where he led commercial efforts related to SEL-212 for the treatment of chronic refractory gout. He has been involved in several gene therapy business development deals, leading to collaborations and licensing deals with AskBio and Sarepta. Mr. Smolinski served as Vice President and Head of Sanofi/Genzyme’s North American Rheumatology Business Unit, leading the company’s commercialization plan for rheumatoid arthritis drug KEVZARA®. Before that, he served as…

The full story can be found on Benzinga.com

Source link

Recommended For You

About the Author: News Center